🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being hailed as a "significant breakthrough" in the battle against superbug strains of the infection, according to health experts.

A Worldwide Public Health Issue

Gonorrhoea infections are on the rise worldwide, with figures suggesting more than 82 million instances per year. Especially elevated rates are observed in the African continent and countries within the WHO's designated area, which spans from China and Mongolia to New Zealand. Across England, cases have hit a all-time high, while figures across Europe in 2023 were triple the level compared to figures for 2014.

“The authorization of new treatments for gonorrhoea is an critical and opportune development in the face of increasing worldwide cases, increasing antimicrobial resistance and the very limited available drugs currently available.”

Medical experts are particularly alarmed about the increase in antibiotic-resistant strains. The World Health Organization has listed it as a "high-priority threat". Recent surveillance showed that the effectiveness of key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Therapies Secure Approval

Zoliflodacin, marketed under the name Nuzolvence, was authorized by the US Food and Drug Administration in mid-December for treating gonorrhoea. This disease can lead to serious health problems, including infertility. Scientists believe that targeted use of this new drug will help delay the development of resistance.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, was also approved in concurrent days. This treatment, which is employed against UTIs, was demonstrated in studies to be able to combat drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin stemmed from a innovative non-profit model for medication research. The non-profit organisation GARDP worked alongside the drug firm Innoviva to see it through.

“This milestone marks a significant shift in the management of multidrug-resistant gonorrhoea, which previously has been staying ahead of medical innovation.”

Research Study Outcomes and Global Access

As per results published in a major medical journal, zoliflodacin eradicated the vast majority of uncomplicated infections. This puts it on an similar efficacy with the typical regimen, which uses an injection and a pill. The study included nearly 1,000 participants from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, the non-profit has the authority to license and sell the drug in a wide range of regions with limited resources.

Doctors treating patients have shared positive views. Having a one-pill regimen like this is described as a "game-changer" for public health efforts. This is deemed crucial to reduce the burden of the disease for patients and to stop the proliferation of untreatable gonorrhoea around the world.